What Happened to Lydac Neuroscience? The Company Connecting Stephen Ray and Andrew Chancellor
The Men Behind Wellbeing — Chapter Seven
We followed Stephen Ray's microvesicle patents and found Lydac Neuroscience Limited. Now Companies House records reveal something considerably more important: both Stephen Ray and Andrew Chancellor served as directors of the company. Years later, Lydac entered administration and liquidation. So what happened—and what became of its intellectual property?
Sometimes an investigation reaches a point where separate pieces of evidence suddenly connect.
This is one of those moments.
In the previous chapters, I established that Stephen Ray is named as inventor on a patent family concerning microvesicles.
The earliest British priority applications date to 2008.
Patent records identify Lydac Neuroscience Limited as the applicant and, in other jurisdictions, proprietor or assignee associated with that intellectual property.
But there was still a major unanswered question.
Where did Andrew Chancellor fit into this story?
We now have an answer.
According to the official UK corporate record, Andrew William Chancellor became a director of Lydac Neuroscience Limited on 26 November 2014.
That means Chancellor and Ray are not connected merely through later Wellbeing biographies or interviews.
There is a documented corporate connection between them through the very company associated with Ray's earlier microvesicle intellectual property.
And what happened to that company afterwards deserves close examination.
Lydac Neuroscience Was Established in 2007
Companies House records show that Lydac Neuroscience Ltd, company number 06369154, was incorporated on 12 September 2007.
Its registered business activity was:
72110 — Research and experimental development on biotechnology.
The company survived for more than seventeen years before ultimately being dissolved on 9 April 2025.
That incorporation date is particularly interesting.
Lydac was established in September 2007.
The first British priority application behind Ray's microvesicle patent family followed only months later, in January 2008.
That chronology strongly supports Lydac's relevance to the early commercial development of the intellectual property.
Stephen Ray Was a Founding Director
Companies House gives us another important piece of the history.
Stephen Ray was appointed a director of Lydac on:
12 September 2007.
That was the company's incorporation date.
He therefore appears in the corporate record from the beginning.
Ray remained a director until:
27 July 2012.
This is significant.
The scientist named as inventor on the microvesicle patent was not simply an outside researcher whose invention happened to be acquired by Lydac.
He was a director of the company from its formation.
And during his directorship, the microvesicle patent applications were filed.
That establishes a much clearer relationship between:
the scientist;
the invention;
and:
the company.
Then Stephen Ray Left the Board
On 27 July 2012, Ray resigned as a director.
That date now becomes important.
Because the intellectual property did not simply disappear when its inventor left the board.
Patent rights belong to their legal owner, not necessarily to the individual inventor.
If Lydac owned those rights, Ray's resignation would not automatically have transferred them back to him.
So we now need to distinguish between two separate things:
Stephen Ray's involvement with Lydac
and:
Lydac's ownership of the intellectual property.
The first changed in 2012.
The second requires separate documentary investigation.
Andrew Chancellor Arrived Two Years Later
Then comes the finding that connects this directly with our wider investigation.
Companies House records:
Andrew William Chancellor
as becoming a director of Lydac Neuroscience on:
26 November 2014.
This matters enormously.
Chancellor has publicly described meeting Stephen Ray and becoming interested in his scientific research before eventually discussing how that research could be commercialised.
We now have a corporate document placing Chancellor inside the company associated with Ray's earlier microvesicle intellectual property.
That moves the story beyond biography.
It gives us a date.
26 November 2014.
The Timeline Is Becoming Much Clearer
We can now construct a documentary chronology.
12 September 2007
Lydac Neuroscience Limited is incorporated.
Stephen Ray becomes a director.
4 January 2008
The first British priority application underlying the microvesicle patent family is filed.
17 March 2008
A second British priority application follows.
2 January 2009
The international patent application is filed.
Patent records identify Stephen Ray as inventor and Lydac Neuroscience Limited as applicant.
27 July 2012
Stephen Ray resigns as a director of Lydac.
26 November 2014
Andrew Chancellor becomes a director.
30 December 2015
The European microvesicle patent EP2240189B1 is published as granted, identifying Lydac as original assignee and Stephen Ray as inventor.
And then, several years later, something goes badly wrong.
Lydac Entered Administration
On 17 December 2018, insolvency practitioners Ian Robert and Christopher Purkiss were appointed administrators of Lydac Neuroscience Limited.
The appointment was formally advertised in The Gazette on 28 December.
The Gazette describes Lydac's business as:
“Research and experimental development on biotechnology.”
More interestingly, its principal trading address was recorded as:
10 Harley Street, London W1G 9PF.
That address deserves attention.
Because Harley Street carries enormous medical prestige.
But an address alone tells us nothing about the scale of a company's clinical operations, laboratory facilities or scientific infrastructure.
Those questions have to be established independently.
Andrew Chancellor Was Still the Recorded Director
This timing is particularly significant.
Companies House records Chancellor's appointment beginning in November 2014.
The company entered administration in December 2018.
The public officer record does not show Chancellor resigning before the insolvency process.
That means Chancellor's connection to Lydac was not merely an early or fleeting historical appointment.
He was the recorded director during the period immediately preceding the company's administration.
That fact deserves scrutiny.
But it must also be handled fairly.
Administration Does Not Prove Misconduct
A company entering administration does not establish wrongdoing by its directors.
Companies fail for many reasons.
They can run out of investment.
Research programmes can fail.
Products can fail commercially.
Patents can prove less valuable than anticipated.
Regulatory problems can delay commercialisation.
Investors can withdraw.
Cash flow can collapse.
None of those possibilities should be assumed here without evidence.
Likewise, Chancellor's position as director does not establish that he personally caused Lydac's financial difficulties.
The correct investigative question is therefore not:
“Did Chancellor cause Lydac to fail?”
It is:
“What did the administrators say caused Lydac to fail?”
That is a question the insolvency documents may be able to answer.
Administration Continued for Almost a Year
Lydac remained in administration from 17 December 2018 until 15 November 2019.
It then exited administration into creditors' voluntary liquidation.
This distinction matters.
Administration is generally intended to rescue a company or its business, achieve a better outcome for creditors than immediate liquidation, or realise assets for secured or preferential creditors.
But Lydac did not emerge from administration as a restored operating biotechnology company.
Instead, it moved into liquidation.
Lydac Entered Creditors’ Voluntary Liquidation
The Gazette records that liquidators were appointed on:
15 November 2019.
The liquidation was described as a:
Creditors' Voluntary Liquidation.
The company's principal trading address remained listed as 10 Harley Street, London.
That tells us something important about the outcome.
The administration had not resulted in Lydac continuing independently as a normal operating company.
The company was instead being wound down.
But for this investigation, that creates a much bigger question.
What Happened to the Patents?
This may be the most important question in Chapter Seven.
When a biotechnology company enters insolvency, intellectual property can be among its most valuable assets.
Patents can potentially be:
sold;
assigned;
licensed;
transferred as part of a business sale;
or retained until expiry.
If Lydac owned valuable rights connected with Stephen Ray's microvesicle technology when administrators were appointed, those rights should potentially have formed part of the company's assets.
So what happened to them?
Were they sold?
If so:
to whom?
For how much?
Was there an existing licence?
Were rights transferred before administration?
Did a connected company acquire them?
Did an investor acquire them?
Did Stephen Ray acquire them?
Did Andrew Chancellor or an organisation connected with him acquire them?
Or did the patents simply remain with Lydac while the company was wound up?
I currently do not have evidence sufficient to answer those questions.
But the insolvency documents may.
The European Patent Adds Another Layer
The European patent record for EP2240189B1 — Microvesicles identifies:
Stephen Ray — inventor
and:
Lydac Neuroscience Ltd — original assignee.
The record shows a priority date of 4 January 2008, filing in January 2009 and publication of the granted European patent on 30 December 2015.
That date is particularly interesting.
The European patent was granted approximately thirteen months after Chancellor joined Lydac's board.
So during Chancellor's directorship, Lydac possessed—or at least was recorded as the original assignee of—granted European intellectual property arising from Ray's earlier work.
That makes the fate of the patent during the later insolvency particularly relevant.
The European Patent Is Now Listed as Not in Force
The current Google Patents record for EP2240189B1 shows its legal status as:
Not-in-force.
That does not, by itself, tell us exactly what happened in every European jurisdiction or to every member of the broader patent family.
Patent families are complicated.
Individual national rights can have different statuses.
Fees may lapse.
Claims may expire.
Different applications may continue separately.
So I am not claiming that all intellectual property arising from Ray's research ceased to exist when this particular record became inactive.
But it creates another legitimate question for anyone valuing the technology today:
Which enforceable patent rights actually remain?
The Company Was Eventually Dissolved
The liquidation continued for years.
Companies House now records Lydac Neuroscience Ltd as:
Dissolved.
The final dissolution occurred on:
9 April 2025.
The company's last accounts were made up to 30 September 2017.
Its last confirmation statement was dated 12 September 2018.
So the corporate entity that once sat alongside Stephen Ray's microvesicle patents no longer exists.
But the science did not disappear.
Stephen Ray did not disappear.
Andrew Chancellor did not disappear.
And today those two names are associated with Wellbeing International Foundation.
That makes the missing period between Lydac's decline and the current operation particularly important.
This Changes Our Understanding of Chancellor and Ray
Earlier in this investigation, Chancellor's account of meeting Ray and discussing commercialisation could have been interpreted as a relatively informal relationship that eventually developed into Wellbeing.
The Companies House evidence gives us something considerably more concrete.
Both men served as directors of the same biotechnology company.
Not simultaneously according to the dates currently established—Ray resigned in 2012 and Chancellor joined in 2014—but within the corporate history of the same entity.
And that entity was directly associated with Ray's microvesicle intellectual property.
That is a major connection.
One Detail Requires Particular Care
It would be tempting to describe Chancellor as having “taken over from Ray.”
The dates might make that narrative attractive.
But the documents presently available do not justify that conclusion.
Ray resigned in July 2012.
Chancellor joined in November 2014.
There was a gap of more than two years.
Other directors existed during that period.
Therefore, we should not manufacture a direct handover unless further corporate records establish one.
The documented position is simpler:
Ray was an early Lydac director.
Ray was the inventor associated with its microvesicle patent.
Ray resigned in 2012.
Chancellor became a director in 2014.
The company entered administration in 2018.
Those facts are strong enough without embellishment.
The Investment Question Now Becomes More Serious
This history takes on additional significance because Wellbeing is now presenting itself as an investment opportunity.
A prospective investor examining a biotechnology business associated with Chancellor and Ray could reasonably ask about the history of the earlier biotechnology company with which both men were associated.
What happened to Lydac?
Why did it enter administration?
How much money had investors or creditors put into it?
What assets remained?
What happened to the patents?
Were those assets sold?
Who acquired them?
And does today's Wellbeing operation legally control technology that once belonged to Lydac?
These aren't accusations.
They are precisely the questions that proper commercial due diligence exists to answer.
There Is One Document I Want Next
We have reached the point where ordinary company profiles are no longer enough.
The document I now want is the administrator's proposal/report.
That report could potentially tell us:
why Lydac became insolvent;
what assets it possessed;
what liabilities it had;
who its major creditors were;
whether intellectual property was valued;
whether patents were sold;
whether there were connected-party transactions;
whether the business or assets were transferred;
and what administrators expected creditors to recover.
If those documents identify what happened to Lydac's patents, we may finally be able to bridge the gap between the old biotechnology company and what came afterwards.
What We Can Establish So Far
The documentary record now gives us a surprisingly detailed skeleton of the company.
Lydac Neuroscience Limited was incorporated in 2007 as a biotechnology research and development company.
Stephen Ray became a director at incorporation and remained until 2012.
Ray is named as inventor on microvesicle intellectual property for which Lydac appears as applicant/original assignee.
Andrew Chancellor became a director in November 2014.
Lydac entered administration on 17 December 2018.
It moved into creditors' voluntary liquidation on 15 November 2019.
And it was finally dissolved on 9 April 2025.
Those are no longer theories.
They are matters appearing in public corporate, insolvency and patent records.
What We Still Cannot Say
We do not yet know from the evidence reviewed here precisely why Lydac became insolvent.
We do not know how much investors lost.
We do not yet know what creditors ultimately recovered.
We have not established that either Chancellor or Ray was criticised by the administrators.
We have not established misconduct by either man.
And critically:
we have not yet established what happened to Lydac's intellectual property.
Those limitations matter.
An investigation becomes stronger—not weaker—when it distinguishes what the documents prove from what still needs proving.
Conclusion: The Corporate Connection Is Now Documented
This chapter began with a question:
What happened to Lydac Neuroscience?
We now know considerably more.
It was not merely an obscure company name attached to an old patent.
It was a biotechnology company founded in 2007.
Stephen Ray was one of its original directors.
His microvesicle technology became intellectual property associated with the company.
Years after Ray left the board, Andrew Chancellor became a director.
During Chancellor's tenure, the European microvesicle patent was granted.
Then in 2018, the company entered administration.
In 2019, it entered creditors' voluntary liquidation.
And in 2025, Lydac Neuroscience Limited finally disappeared from the UK corporate register.
But one potentially valuable thing may have survived the company:
the science.
And that leaves us with the question that could become one of the most important in this entire investigation.
What happened to the intellectual property when Lydac failed?
If the patents or associated technology were sold, assigned, licensed or transferred, the identity of whoever received them could provide the missing link between Stephen Ray's early biotechnology work and the commercial operation surrounding his science today.
That is where we go next.
Next: Chapter Eight — Follow the Money: Inside the Lydac Insolvency
Lydac entered administration while Andrew Chancellor was its director. Now we go inside the insolvency records: what did the company owe, what assets did it possess, what happened to its patents, what did creditors recover—and was the intellectual property transferred before or during the collapse?
Comments